Galmed Medical Research Initiates Phase I Study of Aramchol, Leading Drug Candidate for Fatty Liver Disease
26-Sep-2008 -
Galmed Medical Research Ltd. announced that it has started its Phase-I study in healthy human volunteers of its novel drug, Aramchol, developed for Fatty Liver Disease. This double blind, placebo controlled Phase-I trial was initiated at the Tel-Aviv Sourasky Medical Center (Tel-Aviv, Israel), is ...
drug development
fatty acids
lipids
+1